Johnson & Johnson surprises with Q1 results but shares decline 📉

3:38 pm 15 April 2025

Despite posting stronger-than-expected first-quarter earnings, Johnson & Johnson (JNJ.US) failed to win over investors. The stock slipped slightly on Tuesday, reflecting broader concerns around potential drug tariffs and ongoing legal challenges. Shares fell nearly 1% in premarket trading to around $153, while S&P 500 and Nasdaq futures traded flat—highlighting that the market is no longer reacting enthusiastically to positive earnings alone. The American healthcare giant, with deep roots in pharmaceuticals, biotechnology, and medical technologies, can still boast a solid start to 2025.

Q1 2025 Results J&J:

  • Earnings per Share (EPS): $2.77 vs. $2.69 expected

  • Revenue: $21.9 billion (+2.4% YoY)

  • Updated Operational Sales Outlook (2025): Raised to $92 billion

  • Full-Year Earnings Outlook: Maintained at 6.2% midpoint growth

The company also revised its full-year forecast following the completed acquisition of Intra-Cellular Therapies and the addition of Caplyta—a treatment for bipolar disorder and depression—to its portfolio.

Segment performance

Johnson & Johnson's pharmaceutical segment grew 4.2%, driven by increased sales in oncology, immunology, and cardiovascular therapies. Its MedTech division also expanded 4.1%, supported by acquisitions and asset disposals.

Key regulatory wins:

  • FDA approval of Tremfya for treating Crohn’s disease

  • EU approval of Rybrevant for specific types of lung cancer

These developments reinforce the company's strength in high-demand specialty drug markets.

Tariffs and Lawsuits: Ongoing Headwinds

Investor concerns have been further fueled by signals out of Washington. Former President Donald Trump recently hinted at new tariffs targeting the pharmaceutical sector. Just before the earnings release, regulators launched an investigation into U.S. drug imports—potentially laying the groundwork for further trade restrictions.

This uncertainty likely contributed to the market’s muted response to the otherwise strong earnings.

Simultaneously, J&J continues to battle long-standing legal cases related to its talc-based baby powder. In March, a Texas court blocked the company’s attempt to offload legal liabilities through a bankruptcy filing by its subsidiary, Red River Talc.

  • J&J claims the lawsuits are unfounded and based on “junk science.”

  • The company alleges part of the litigation is funded by foreign investment funds.

  • J&J has stated it will not settle and plans to recover up to $7 billion from legal reserves.

Despite ongoing legal and macroeconomic risks, Johnson & Johnson remains a favored defensive play. Its diversified product base and exposure across healthcare segments provide stability during turbulent times. Still, the brewing trade war scenario could weigh on sentiment, which might explain Wall Street’s current caution. Since the announcement of potential drug tariffs on April 2, J&J shares have slipped only 0.6%, while the S&P 500 is down nearly 5% over the same period. Year-to-date, J&J stock is up over 6%, a strong performance compared to the broad market’s 8% decline.

Earnings Summary

  • Beat expectations on both revenue and EPS

  • Raised 2025 operational sales guidance

  • Growth in pharma and MedTech divisions

  • Facing tariff risk and talc-related lawsuits

  • Stock remains a defensive play in volatile markets

Johnson & Johnson Stock (Daily Chart)

While J&J shares have gained modestly this year, the stock remains in a longer-term downtrend. A key technical resistance level sits at the 200-day EMA (~$157). Despite its solid business, the current P/E ratio of 18 appears relatively high, especially considering the company operates in a mature, less growth-oriented sector that could be impacted by future pharma tariffs.

Source: xStation5

Jonhson & Johnson Financial dashboard

Source: XTB Research, Bloomberg Finance L.P.

The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.

Share:
Back

Join over 1 400 000 XTB Group Clients from around the world.